Direct comparison of doses did not show evidence of dose dependence for blood pressure-lowering for any of the other thiazides for which RCT data were available : bendrofluazide , chlorthalidone , cyclopenthiazide , metolazone or indapamide .
This is based on an informal indirect comparison of results observed in other Cochrane review s on ACE inhibitors , ARBs and renin inhibitors compared with placebo , which used similar inclusion /exclusion criteria to the present review .Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides .
These effects were dose-related and were least for hydrochlorothiazide .
Chlorthalidone increased serum glucose but the evidence was unclear for other thiazides .
This systematic review shows that hydrochlorothiazide has a dose-related blood pressure-lowering effect .
Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides
BACKGROUND Hypertension is a modifiable cardiovascular risk factor .
Although it is established that low-dose thiazides reduce mortality as well as cardiovascular morbidity , the dose-related effect of thiazides in decreasing blood pressure has not been subject to a rigorous systematic review .
It is not known whether individual drugs within the thiazide diuretic class differ in their blood pressure-lowering effects and adverse effects .
OBJECTIVES To determine the dose-related decrease in systolic and /or diastolic blood pressure due to thiazide diuretics compared with placebo control in the treatment of patients with primary hypertension .
Secondary outcomes included the dose-related adverse events leading to patient withdrawal and adverse biochemical effects on serum potassium , uric acid , creatinine , glucose and lipids .
Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects.
OBJECTIVE --To determine the relevant dose of bendrofluazide for treating mild to moderate hypertension . DESIGN --Double blind parallel group trial of patients who were given placebo for six weeks and then r and omly allocated to various doses of bendrofluazide ( 1.25 , 2.5 , 5 , or 10 mg daily ) or placebo for 12 weeks . SETTING --General practice s in Zeal and , Denmark . PATIENTS --257 Patients with newly diagnosed or previously treated hypertension , aged 25 - 70 , who had a mean diastolic blood pressure of 100 - 120 mm Hg after receiving placebo for six weeks . MAIN OUTCOME MEASURES --Reduction in diastolic blood pressure and changes in biochemical variables ( potassium , urate , glucose , fructosamine , total cholesterol , apolipoprotein A I , apolipoprotein B , and triglyceride concentrations ) . RESULTS --All doses of bendrofluazide significantly reduced diastolic blood pressure to the same degree ( 10 - 11 mm Hg ) . Clear relations between dose and effect were shown for potassium , urate , glucose , total cholesterol , and apolipoprotein B concentrations . The 1.25 mg dose increased only urate concentrations , whereas the 10 mg dose affected all the above biochemical variables . CONCLUSION --The relevant range of doses of bendrofluazide to treat mild to moderate hypertension is 1.25 - 2.5 mg a day . Higher doses caused more pronounced adverse biochemical effects including adverse lipid effects . Previous trials with bendrofluazide have used too high doses
Direct comparison of doses did not show evidence of dose dependence for blood pressure-lowering for any of the other thiazides for which RCT data were available : bendrofluazide , chlorthalidone , cyclopenthiazide , metolazone or indapamide .
This is based on an informal indirect comparison of results observed in other Cochrane review s on ACE inhibitors , ARBs and renin inhibitors compared with placebo , which used similar inclusion /exclusion criteria to the present review .Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides .
These effects were dose-related and were least for hydrochlorothiazide .
Chlorthalidone increased serum glucose but the evidence was unclear for other thiazides .
This systematic review shows that hydrochlorothiazide has a dose-related blood pressure-lowering effect .
Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides
BACKGROUND Hypertension is a modifiable cardiovascular risk factor .
Although it is established that low-dose thiazides reduce mortality as well as cardiovascular morbidity , the dose-related effect of thiazides in decreasing blood pressure has not been subject to a rigorous systematic review .
It is not known whether individual drugs within the thiazide diuretic class differ in their blood pressure-lowering effects and adverse effects .
OBJECTIVES To determine the dose-related decrease in systolic and /or diastolic blood pressure due to thiazide diuretics compared with placebo control in the treatment of patients with primary hypertension .
Secondary outcomes included the dose-related adverse events leading to patient withdrawal and adverse biochemical effects on serum potassium , uric acid , creatinine , glucose and lipids .